EGFR and familial pancreatic carcinoma: The monoclonal anti-EGFR antibody cetuximab and the EGFR tyrosine kinase inhibitor erlotinib led (in monotherapy or in combination with cytotoxic drugs) to improved survival in patients with colorectal cancer, non-small cell lung cancer and advanced pancreatic cancer [41]–[43].